Tissue Diagnostics Market worth $10.86 billion by 2030 | MarketsandMarkets™
DELRAY BEACH, Fla., Feb. 10, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Tissue Diagnostics Market is projected to grow from about...
Cancer
SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems
BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today...
/C O R R E C T I O N — Conexiant/
In the news release, ASCO and Conexiant Launch ASCO AI in Oncology, a Premium Digital Destination Connecting Brands with Oncology...
Leading Board-Certified Plastic Surgeon Dr. David W. Allison Moves to New Princeton Location on Bunn Drive
Experienced plastic surgeon relocates to Princeton, offering face, breast, body, and reconstructive procedures. PRINCETON, NEW JERSEY / ACCESS Newswire /...
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
HOUSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with...
RenovoRx Establishes RenovoCath® Medical Advisory Board
Advisory Board Members Will Provide Strategic Clinical Insights to Further Advance the TAMP™ Therapy Platform in Clinical Indications of High...
Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline
AGOURA HILLS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- via IBN — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the...
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical...
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on...
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency...
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health securityStrategic...
Health Canada cannabis guidance exposes “absurd” education gap in healthcare
- Apothecare calls for medical cannabis education to be integrated into clinical training and standard practice, not left to patients...
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and...
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a...
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for...
Phio Announces Safety Monitoring Committee’s (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in...
Protai to showcase groundbreaking AIMS™ drug discovery platform and best-in-class PRT001 KAT6A degrader results at spring 2026 global conferences.
TEL AVIV, Israel, Feb. 10, 2026 /PRNewswire/ -- Protai, www.protai.bio, an AI drug discovery startup, announced its participation in a series of...
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"),...
Medical biotech Ferronova completes enrolment for gastric and oesophageal cancer image-guided surgery trial.
ADELAIDE, Australia, Feb. 9, 2026 /PRNewswire/ -- Australian company Ferronova announced today it has completed enrolment of patients for its two-year...